Medtronic Is Not Going With The EOFlow – Deal Cancelled
Medtronic is dropping plans to acquire EOFlow, which has faced numerous patent lawsuits from Insulet.
You may also be interested in...
The two diabetes players announced a new integration between their products.
Embecta, which recently completed its spin-off from Becton Dickinson, is forging ahead with its insulin injector-based business strategy, GLP-1s be damned.
Insulet and EOFlow have been locked in a legal dispute for more than two months now, however it seems EOFlow may be on the back foot, after having an injunction made against it. This could have major implications for the wider diabetes sector, as a whole.